OncoMatch/Clinical Trials/NCT06096844
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Is NCT06096844 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for advanced lung non-small cell carcinoma.
Treatment: Carboplatin · Nab-paclitaxel · Paclitaxel · Pembrolizumab · Pemetrexed — This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) Tumor Proportion Score (TPS) range of 1-49% (1-49%)
PD-L1 Tumor Proportion Score (TPS) range of 1-49%
Required: EGFR wild-type
tumor that is negative for EGFR mutation
Required: ALK wild-type
tumor that is negative for ... ALK translocations
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 2–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Exception: Chemotherapy given in the setting of adjuvant therapy or locally advanced disease is allowed as long as treatment was completed, and they have fully recovered from treatment related adverse events prior to Step 1 registration
Patient must not have had any prior cytotoxic chemotherapy regimen for metastatic disease
Cannot have received: immunotherapy
Exception: Immunotherapy given in the setting of adjuvant therapy or locally advanced disease is allowed as long as treatment was completed greater than 6 months prior to Step 1 registration
Patient must not have had any prior immunotherapy for metastatic disease
Lab requirements
Blood counts
Absolute neutrophil count (ANC) 1,500/uL; Platelets 75,000/uL; Hemoglobin (Hgb) 8.0 g/dL
Kidney function
Creatinine clearance (CrCL) 45 mL/min (estimated using Cockcroft-Gault method with actual body weight or measured)
Liver function
Total bilirubin 1.5 x institutional upper limit of normal (ULN); AST and ALT 3.0 d7 institutional ULN
ANC 1,500/uL; Platelets 75,000/uL; Hemoglobin (Hgb) 8.0 g/dL; Total bilirubin 1.5 x institutional ULN; AST and ALT 3.0 d7 institutional ULN; Creatinine clearance (CrCL) 45 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group - Fayetteville · Fayetteville, Arkansas
- Mercy Hospital Fort Smith · Fort Smith, Arkansas
- Highlands Oncology Group - Rogers · Rogers, Arkansas
- Highlands Oncology Group · Springdale, Arkansas
- Kaiser Permanente Dublin · Dublin, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify